Dyne Therapeutics (NASDAQ:DYN) Raised to "Strong-Buy" at Jones Trading

Jones Trading upgraded shares of Dyne Therapeutics (NASDAQ:DYN - Free Report) to a strong-buy rating in a research report report published on Wednesday morning,Zacks.com reports.

Several other brokerages also recently weighed in on DYN. Sanford C. Bernstein initiated coverage on Dyne Therapeutics in a research note on Tuesday, June 24th. They set a "market perform" rating and a $13.00 target price for the company. Raymond James Financial initiated coverage on shares of Dyne Therapeutics in a research report on Wednesday, June 11th. They set an "outperform" rating and a $37.00 price target on the stock. Scotiabank initiated coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target on the stock. HC Wainwright reduced their price target on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, June 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Dyne Therapeutics has an average rating of "Moderate Buy" and an average price target of $41.13.

Dyne Therapeutics Stock Down 0.5%

Shares of Dyne Therapeutics stock traded down $0.05 during trading hours on Wednesday, hitting $9.52. 1,450,841 shares of the company's stock traded hands, compared to its average volume of 1,762,437. The stock has a 50 day simple moving average of $11.83 and a 200-day simple moving average of $13.66. The company has a market cap of $1.08 billion, a PE ratio of -2.65 and a beta of 1.17. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, equities research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

Large investors have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new position in Dyne Therapeutics in the fourth quarter worth about $2,340,000. Schroder Investment Management Group increased its stake in shares of Dyne Therapeutics by 63.3% in the fourth quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock valued at $3,477,000 after purchasing an additional 56,961 shares during the period. Rhumbline Advisers increased its stake in shares of Dyne Therapeutics by 4.2% in the first quarter. Rhumbline Advisers now owns 133,627 shares of the company's stock valued at $1,398,000 after purchasing an additional 5,383 shares during the period. Wells Fargo & Company MN increased its stake in shares of Dyne Therapeutics by 54.5% in the fourth quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock valued at $913,000 after purchasing an additional 13,677 shares during the period. Finally, Swiss National Bank increased its stake in shares of Dyne Therapeutics by 3.3% in the fourth quarter. Swiss National Bank now owns 108,600 shares of the company's stock valued at $2,559,000 after purchasing an additional 3,500 shares during the period. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.